Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

Beximco Pharmaceuticals considers board changes, possible resignation of Salman F Rahman

Beximco Pharmaceuticals has announced proposed changes to its board, including the potential resignation of vice chairman Salman F Rahman. The move responds to media reports and is part of negotiations with the Bangladesh Securities and Exchange Commission (BSEC) to resolve two legal matters concerning the appointment of nine additional independent non‑executive directors and the convening of a meeting. Any appointment is subject to a final agreement with the BSEC and a due diligence review by the Nominated Adviser under AIM rules. » Mere på de.investing.com
Beximco Pharmaceuticals: court hearings in BSEC dispute postponed until after April

Hearings on two lawsuits challenging orders by the securities regulator BSEC will not begin until after April 18 because of the court vacation of the High Court Division of Bangladesh. One case challenges the proposed appointment of nine independent non-executive directors (Case No. 525/2025), and the other challenges the order to hold a meeting to appoint these directors (Case No. 1243/2026). » Mere på de.investing.com
Beximco Pharmaceuticals: GDR trading on AIM suspended from 2 January 2026

Beximco Pharmaceuticals is temporarily suspending trading of its Global Depositary Receipts (GDRs) on the AIM in London from 2 January 2026 because it cannot publish its annual results for the year ended 30 June 2025 on time. The delay is caused by a postponement in convening a board meeting, due to a pending High Court proceeding in Bangladesh concerning the appointment of additional independent directors; the case must be reheard after the judicial benches are reconstituted. The company expects a court decision no earlier than January 2026 and stresses that its shares will continue to be traded on the Dhaka Stock Exchange and the Chittagong Stock Exchange and that reportable developments will be announced. » Mere på de.investing.com

Historisk udbytte Udbytte

I 2025 har Beximco Pharmaceuticals ADR allerede udloddet 0,0315 € i udbytte. Den seneste udlodning fandt sted i februar 2025.

Fundamentale data

Nøgletal	Værdi
Markedsværdi	288,97 mio. €
Antal aktier	446,11 mio.
Højeste/laveste i 52 uger	0,78 € - 0,0051 €
Udbytte	Nej
Beta	0,25
P/E (PE Ratio)	4,70
PEG (PEG Ratio)	0,17
K/I (PB Ratio)	0,68
P/S (PS Ratio)	0,75

Virksomhedsprofil

Beximco Pharmaceuticals Limited fremstiller og markedsfører generiske farmaceutiske formuleringsprodukter og aktive farmaceutiske ingredienser i Bangladesh. Virksomheden tilbyder produkter inden for allergiske lidelser, smertestillende og febernedsættende midler, anti-infektiøse midler, antivirale midler, kardiovaskulære midler, midler til centralnervesystemet, hoste- og forkølelsesmidler, endokrine midler og diabetes, øjenpleje, mave-tarm-midler, hormon- og steroidmidler, intravenøs væske, muskel- og skeletmidler, onkologi, luftvejsmidler, urogenitale midler, hudpleje, vitamin- og mineraltilskud samt andre produkter, og den leverer desuden kontraktfremstillingsydelser til andre virksomheder. Den leverer sine produkter i forskellige doseringsformer, herunder faste stoffer, væsker, creme og salve, stikpiller, doseret aerosol og tørpulverinhalator, næsespray, sterile, frysetørrede injicerbare produkter samt store volumener af intravenøs væske. Virksomheden eksporterer også sine produkter. Beximco Pharmaceuticals Limited blev stiftet i 1976 og har hovedkontor i Dhaka, Bangladesh.